24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Clinical trial NCT05549219 · COMPLETED

Trial details

NCT number: NCT05549219
Sponsor: Glycomine, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pmm2-CDG Phosphomannomutase 2 Deficiency

Start date: 2022-11-29
Primary completion: 2025-11-04
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.